These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 27471683)
1. Immunotherapy in the management of melanoma: current status. Alston D; Brewer JD Immunotargets Ther; 2013; 2():1-10. PubMed ID: 27471683 [TBL] [Abstract][Full Text] [Related]
2. Vemurafenib and ipilimumab: new agents for metastatic melanoma. Banaszynski M; Kolesar JM Am J Health Syst Pharm; 2013 Jul; 70(14):1205-10. PubMed ID: 23820456 [TBL] [Abstract][Full Text] [Related]
3. Ipilimumab and vemurafenib: two different routes for targeting melanoma. Burgeiro A; Mollinedo F; Oliveira PJ Curr Cancer Drug Targets; 2013 Oct; 13(8):879-94. PubMed ID: 23862981 [TBL] [Abstract][Full Text] [Related]
4. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue". Jarkowski A; Norris L; Trinh VA Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920 [TBL] [Abstract][Full Text] [Related]
5. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. Babiker HM; Riaz IB; Husnain M; Borad MJ Oncolytic Virother; 2017; 6():11-18. PubMed ID: 28224120 [TBL] [Abstract][Full Text] [Related]
6. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond. Zhu Z; Liu W; Gotlieb V Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040 [TBL] [Abstract][Full Text] [Related]
7. [Unblocking antitumor immune response: novel possibilities for the immunotherapy of melanoma]. Ladányi A; Balatoni T Magy Onkol; 2013 Jun; 57(2):100-7. PubMed ID: 23795355 [TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in melanoma: Recent advances and future directions. Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635 [TBL] [Abstract][Full Text] [Related]
11. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767 [TBL] [Abstract][Full Text] [Related]
12. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs. Loo K; Daud AI Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249 [TBL] [Abstract][Full Text] [Related]
19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
20. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies. Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]